Tumor and immune signatures linked to GD2 therapy in kids with neuroblastoma
Official title: Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastoma
Funded at Emory University · NIH-11384562 · Data updated 2026-11-12
A study in children with high‑risk neuroblastoma looks for immune system patterns that predict how well GD2 antibody therapy works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $565,657 |
| NIH project number | 5R01CA285566-03 |
| Project ID | NIH-11384562 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children newly diagnosed with high‑risk neuroblastoma enrolled in the GD2 chemoimmunotherapy regimen (ANBL2131) and who have biospecimens available for immune profiling.
✕Less likely to help
Children whose tumor or immune tissue samples are not analyzable or who do not undergo GD2-directed therapy may not benefit from this study.
What this research studies
This project will analyze tumor tissue and a child’s blood to map immune cells and signals before and after GD2-directed chemoimmunotherapy. Researchers will use advanced techniques like single‑cell genomics, proteomics, mass cytometry, and functional tests on biospecimens from the ON pediatric trial to identify biomarkers of response or resistance. The goal is to understand how tumor and host immunity together influence outcomes and to uncover factors such as germline variation and early life exposures that shape immune fitness. Findings could guide more personalized treatment approaches and future therapeutic strategies for neuroblastoma.
Why it matters
Potential benefit: Identifying immune biomarkers could help tailor GD2 therapy to each child and improve survival through more effective, individualized treatment plans.
How similar studies have gone: Prior work has shown that immune environment and circulating immune cells can influence antibody therapy outcomes in cancers; this study extends those findings to neuroblastoma with comprehensive profiling.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Goldsmith, Kelly C — Emory University
- Study coordinator: Goldsmith, Kelly C
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.